Free Trial

Guided Therapeutics Q2 2024 Earnings Report

Guided Therapeutics logo
$0.08 0.00 (0.00%)
As of 04/3/2025

Guided Therapeutics EPS Results

Actual EPS
-$0.01
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Guided Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Guided Therapeutics Announcement Details

Quarter
Q2 2024
Time
N/A

Conference Call Resources

Remove Ads

Guided Therapeutics Earnings Headlines

Your Retirement Is Caught in the Crossfire
When Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. Now… as new tariffs take effect, gold is breaking records again. You've hopefully already seen this in action… but gold is surpassing $3,000 per ounce for the first time EVER.
Guided Therapeutics Inc (GTHP)
See More Guided Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Guided Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Guided Therapeutics and other key companies, straight to your email.

About Guided Therapeutics

Guided Therapeutics (OTCMKTS:GTHP), a medical technology company, focuses on developing medical devices. It focuses on the commercialization of LuViva, a non-invasive cervical cancer detection device that identifies cervical cancers and precancers painlessly, non-invasively, and at the point-of-care by scanning the cervix with light, then analyzing the light reflected and fluorescent light. The company was formerly known as SpectRx, Inc. and changed its name to Guided Therapeutics, Inc. in February 2008. Guided Therapeutics, Inc. was incorporated in 1992 and is based in Norcross, Georgia.

View Guided Therapeutics Profile

More Earnings Resources from MarketBeat